<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. MRNA, -3.59% gained 0.1% on Friday after the company said it is now developing mRNA vaccines for herpes simplex virus, varicella-zoster virus (against shingles), and certain types of cancer, starting with advanced or metastatic melanoma and non-small cell lung carcinoma. The company’s stock is down 13.7% over the past year, while the broader S&P 500 SPX, -2.12% is 11.4%.
...read full article on Market Watch
